Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A new era in the treatment of melanoma: from biology to clinical practice.

Literature DB >> 22082642

A new era in the treatment of melanoma: from biology to clinical practice.

I Márquez-Rodas¹, S Martín Algarra, J A Avilés Izquierdo, S Custodio Cabello, M Martín.

Abstract

Melanoma is the deadliest cutaneous malignancy and its incidence continues to grow. Until 2011, the treatment options for metastatic melanoma were scarce and without any overall survival benefit. The emergence of new targeted therapies for BRAF mutant melanoma (vemurafenib) and immunotherapy (ipilimumab) has changed the standard of care for this disease. The objective of the present review is to summarise the biological background of the new therapeutic approaches in melanoma, focusing on apoptosis resistance, immune modulation and angiogenesis, and the direct translation into clinical practice.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2011 PMID： 22082642 DOI： 10.1007/s12094-011-0734-6

Source DB: PubMed Journal: Clin Transl Oncol ISSN： 1699-048X Impact factor: 3.405

42 in total

1. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors: Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal: J Invest Dermatol Date: 2006-01 Impact factor: 8.551

Review 2. Staging and prognosis of cutaneous melanoma.

Authors: Paxton V Dickson; Jeffrey E Gershenwald
Journal: Surg Oncol Clin N Am Date: 2011-01 Impact factor: 3.495

3. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

Authors: L Serrone; M Zeuli; F M Sega; F Cognetti
Journal: J Exp Clin Cancer Res Date: 2000-03

4. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors: Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal: Cancer Res Date: 2010-06-15 Impact factor: 12.701

Review 5. Spontaneous regression of metastases from melanoma: review of the literature.

Authors: Louise Vennegaard Kalialis; Krzysztof T Drzewiecki; Helle Klyver
Journal: Melanoma Res Date: 2009-10 Impact factor: 3.599

Review 6. Melanoma: molecular pathogenesis and emerging target therapies (Review).

Authors: Alessia E Russo; Elena Torrisi; Ylenia Bevelacqua; Rosario Perrotta; Massimo Libra; James A McCubrey; Demetrios A Spandidos; Franca Stivala; Grazia Malaponte
Journal: Int J Oncol Date: 2009-06 Impact factor: 5.650

Review 7. Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors: Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal: Mayo Clin Proc Date: 2008-07 Impact factor: 7.616

Review 8. Recent concepts of antiangiogenic therapy.

Authors: Hiroyuki Konno; Masayoshi Yamamoto; Manabu Ohta
Journal: Surg Today Date: 2010-05-23 Impact factor: 2.549

Review 9. Angiogenesis in melanoma.

Authors: Ganapati H Mahabeleshwar; Tatiana V Byzova
Journal: Semin Oncol Date: 2007-12 Impact factor: 4.929